Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 5;49(1):385–389. doi: 10.1007/s00259-021-05423-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — [⁶⁸ Ga]Ga-FAPI-04 PET/CT in patients with castration-resistant prostate cancer. Maximum intensity projections of three patients undergoing [⁶⁸ Ga]Ga-FAPI-04 PET/CT: (A) A 77-year-old patient diagnosed with PC in 2001, progressing after standard androgen deprivation therapy, abiraterone, docetaxel, enzalutamide, cabazitaxel, and [¹⁷⁷Lu]Lu-PSMA-617-RLT; [⁶⁸ Ga]Ga-FAPI-04 PET/CT demonstrating bone and LN metastases; another image of this patient has been published previously [14]; (B) A 70-year-old patient diagnosed with PC in 2007 undergoing radical prostatectomy (pT3b, pN1, R1, GS 5 + 3 = 9, ISUP 5, M0) followed by radiation to the prostatic bed and pelvic LN, first-generation antiandrogen therapy, multiple resections of pulmonary metastases, docetaxel chemotherapy, and enzalutamide, finally progressing under treatment with olaparib (confirmed somatic BRCA2 mutation); [⁶⁸ Ga]Ga-FAPI-04 PET/CT demonstrating bone and pulmonary metastases; (C) A 71-year-old patient initially diagnosed with metastatic PC in 2016 presenting a mixed phenotype of 20% adenocarcinoma and 80% neuroendocrine cancer. Currently progressing after treatment with three-cycle cisplatin/etoposide chemotherapy and immunotherapy (nivolumab + ipilimumab); [⁶⁸ Ga]Ga-FAPI-04 PET/CT demonstrating bone and LN metastases; a different image of this patient has been published previously in another context [10]